TOVX

Theriva Biologics, Inc.
CAPPED RATING

Theriva Biologics, Inc. (TOVX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (D). The rating has held at C for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B
Factor Score 3.3 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.2
EV / EBITDA -0.2
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -41.7%
Price Return 12M -53.3%
Catalyst Signal 0.00
Market Cap $6.6M
TTM Revenue $300.0K
Price / Sales 22.0
ROE -99.8%

Historical Factor Score Progression

Held C for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B (3.3) D (1.4) C (2.2) D+ (1.7) C+ (2.6) C (2.3)
2026-11-08 B+ (3.5) D (1.4) C (2.2) C- (2.0) C+ (2.6) C (2.3)
2026-11-01 B (3.4) D (1.3) C (2.2) C- (1.9) C+ (2.7) C (2.3)
2026-10-25 B (3.3) D (1.3) C (2.2) C- (2.1) C+ (2.6) C (2.3)
2026-10-18 B (3.3) D (1.3) C (2.2) C (2.3) C+ (2.6) C (2.3)
Page 1 of 3